WO2001074379A3 - Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors - Google Patents

Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors Download PDF

Info

Publication number
WO2001074379A3
WO2001074379A3 PCT/US2001/009451 US0109451W WO0174379A3 WO 2001074379 A3 WO2001074379 A3 WO 2001074379A3 US 0109451 W US0109451 W US 0109451W WO 0174379 A3 WO0174379 A3 WO 0174379A3
Authority
WO
WIPO (PCT)
Prior art keywords
inducing angiogenesis
morphogenic protein
methods
morphogenic proteins
mammal
Prior art date
Application number
PCT/US2001/009451
Other languages
French (fr)
Other versions
WO2001074379A2 (en
Inventor
Ugo Ripamonti
Lentsha Nathaniel Ramoshebi
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Priority to CA002402586A priority Critical patent/CA2402586A1/en
Priority to JP2001572121A priority patent/JP2003528922A/en
Priority to AU2001250962A priority patent/AU2001250962A1/en
Priority to EP01924295A priority patent/EP1267910A2/en
Publication of WO2001074379A2 publication Critical patent/WO2001074379A2/en
Publication of WO2001074379A3 publication Critical patent/WO2001074379A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method for inducing angiogenesis at a target locus in a mammal using morphogenic proteins. In addition, this invention also features a method for improving the angiogenic capability of a morphogenic protein at a target locus in a mammal. In this method, the morphogenic protein is capable of inducing angiogenesis when accessible to a progenitor cell in the mammal, and the morphogenic protein stimulatory factor enhances that capability. The morphogenic protein and morphogenic protein stimulatory factor can be administered simultaneously to the target locus. Alternatively, the two components are administered separately, in any order.
PCT/US2001/009451 2000-03-31 2001-03-23 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors WO2001074379A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002402586A CA2402586A1 (en) 2000-03-31 2001-03-23 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
JP2001572121A JP2003528922A (en) 2000-03-31 2001-03-23 Methods for inducing angiogenesis using morphogenic proteins and morphogenic protein stimulating factors
AU2001250962A AU2001250962A1 (en) 2000-03-31 2001-03-23 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
EP01924295A EP1267910A2 (en) 2000-03-31 2001-03-23 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/540,466 2000-03-31
US09/540,466 US20030104977A1 (en) 2000-03-31 2000-03-31 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors

Publications (2)

Publication Number Publication Date
WO2001074379A2 WO2001074379A2 (en) 2001-10-11
WO2001074379A3 true WO2001074379A3 (en) 2002-03-21

Family

ID=24155572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009451 WO2001074379A2 (en) 2000-03-31 2001-03-23 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors

Country Status (6)

Country Link
US (1) US20030104977A1 (en)
EP (1) EP1267910A2 (en)
JP (1) JP2003528922A (en)
AU (1) AU2001250962A1 (en)
CA (1) CA2402586A1 (en)
WO (1) WO2001074379A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363965C (en) 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
CN102369017A (en) * 2009-02-12 2012-03-07 史赛克公司 Compositions and methods for minimally invasive systemic delivery of proteins comprising TGF-beta superfamily members
CA2752157A1 (en) * 2009-02-12 2010-08-19 Stryker Corporation Peripheral administration of proteins including tgf-.beta. superfamily members for systemic treatment of disorders and disease
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
US20160220640A1 (en) * 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
US10980857B2 (en) 2016-01-06 2021-04-20 President And Fellows Of Harvard College Treatment with GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
WO2019144053A1 (en) * 2018-01-19 2019-07-25 President And Fellows Of Harward College Gdf11 variants and uses thereof
CN114470162B (en) * 2022-01-28 2023-02-03 浙江大学 Application of GDF6 and over-expression reagent thereof in preparation of myocardial cell protective agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029718A2 (en) * 1997-12-10 1999-06-17 Genetics Institute, Inc. Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions thereof
US6034062A (en) * 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008196A (en) * 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5324819A (en) * 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5284756A (en) * 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
WO1993009229A1 (en) * 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
MX9706283A (en) * 1996-08-19 1998-02-28 Hoechst Ag New polyene antibiotics, 3874 h1 to h6, processs for their preparation and employment.
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
AU1276399A (en) * 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034062A (en) * 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
WO1999029718A2 (en) * 1997-12-10 1999-06-17 Genetics Institute, Inc. Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RAMOSHEBI LENTSHA NATHANIEL ET AL: "Osteogenic protein-1, a bone morphogenetic protein, induces angiogenesis in the chick chorioallantoic membrane and synergizes with basic fibroblast growth factor and transforming growth factor-beta1.", ANATOMICAL RECORD, vol. 259, no. 1, 1 May 2000 (2000-05-01), pages 97 - 107, XP001030846, ISSN: 0003-276X *
See also references of EP1267910A2 *
YEH LEE-CHUAN C ET AL: "Osteogenic protein-1 increases gene expression of vascular endothelial growth factor in primary cultures of fetal rat calvaria cells.", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 153, no. 1-2, 20 July 1999 (1999-07-20), pages 113 - 124, XP001030803, ISSN: 0303-7207 *

Also Published As

Publication number Publication date
EP1267910A2 (en) 2003-01-02
JP2003528922A (en) 2003-09-30
US20030104977A1 (en) 2003-06-05
WO2001074379A2 (en) 2001-10-11
CA2402586A1 (en) 2001-10-11
AU2001250962A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
WO2001074379A3 (en) Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
WO2001075087A3 (en) Subtilisin variants
BG104828A (en) Fap alpha-specific antibody with improved pruducibility
EP2016953A3 (en) Vascular endothelial cell growth factor antagonists and uses thereof
MXPA02007733A (en) Enhancing the circulating half life of antibody based fusion proteins.
WO2001072264A3 (en) Pro-liposomal encapsulated preparations (iv)
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
AU2001232833A1 (en) Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
WO2002046409A3 (en) Proteins and nucleic acids encoding same
WO2004067555A3 (en) Protein and peptide delivery to mammalian cells in vitro
WO2001094949A3 (en) Soluble cd1 compositions and uses thereof
WO2004055041A3 (en) Defensin-inducing peptides from fusobacterium
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
AU2001240025A1 (en) Cell cycle proteins associated with rad9, compositions and methods of use
AU2001241610A1 (en) Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
WO2005017237A3 (en) Apparatus and method for the selective assembly of protein
EP0885959A3 (en) Human Wnt-5b protein
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
NO20022101L (en) Peptides for the treatment of erectile dysfunction
WO2002009644A3 (en) Angiogenic and osteogenic proteins for use in enhancing bone density and formation
WO2002046408A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
IL129273A (en) Monoclonal antibody to placental protein 13 and immunoassay and kit using said antibody
AU2002350515A1 (en) Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
WO2001077147A3 (en) New bromodomain protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2001250962

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2402586

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001924295

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 572121

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001924295

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001924295

Country of ref document: EP